Novo Nordisk reaches a milestone in stopping animal testing

Danish insulin giant Novo Nordisk (NVO: N) has released a video highlighting that, effective yesterday (November 28), it will no longer use living animals to test the quality of the batches of medicine coming out of the company’ production lines. These tests have for years been required by health authorities as part of their approval of the products.

“Today’s achievement is a milestone in our ongoing commitment to animal ethics in Novo Nordisk. We have been working for more than a decade, in close collaboration with regulatory authorities around the world, to eliminate obsolete tests or develop and certify new laboratory assays that can be used instead of animals to evaluate the consistent quality of our marketed products,” says the firm’s executive vice president and chief science officer, Mads Krogsgaard Thomsen.

Commitment to “3R principles”